Polysaccharide from Panax japonicus CA Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice

被引:10
作者
Wu, Yi [1 ]
Yin, Wen [1 ]
Hao, Ping [1 ]
Chen, Yueru [1 ,3 ]
Yu, Lingyun [1 ]
Yu, Xingjian [4 ]
Wu, Yu [1 ,5 ]
Li, Xiaocong [6 ]
Wang, Wenjia [1 ,7 ]
Zhou, Hui [1 ]
Yuan, Yuan [1 ]
Quan, Xiaoyu [1 ]
Yu, Yue [1 ]
Hu, Bing [1 ]
Chen, Shouhai [1 ]
Zhou, Zhenlei [1 ]
Sun, Wenjing [2 ]
机构
[1] Nanjing Agr Univ, Coll Vet Med, Nanjing 210095, Peoples R China
[2] Yulin Normal Univ, Coll Biol & Pharm, Guangxi Key Lab Agr Resources Chem & Biotechnol, 1303 Jiaoyu East Rd, Yulin 537000, Peoples R China
[3] Shandong Univ Tradit Chinese Med, Coll Pharm, Jinan 250355, Peoples R China
[4] Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA
[5] Nanjing Med Univ, Ctr Global Hlth, Dept Pathogen Biol & Immunol, Jiangsu Key Lab Pathogen Biol, Nanjing 211166, Jiangsu, Peoples R China
[6] Hubei Three Gorges Polytech, 31 Stadium Rd, Yichang 443000, Peoples R China
[7] Ningxia Univ, Coll Anim Sci & Technol, Yinchuan, Peoples R China
基金
中国国家自然科学基金;
关键词
China; Panax japonicus polysaccharides; Non-alcoholic fatty liver disease; Gut microbiota; Metabolism; NAFLD;
D O I
10.1016/j.ijbiomac.2024.129430
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, a new polysaccharide (PSPJ) with specific molecular weight and monosaccharide compositions was isolated and purified from the water extract of Panacis Japonici Rhizoma (PJR). 16S rRNA analysis and untargeted metabolomic analysis were used to assess PSPJ's efficacy in averting non-alcoholic fatty liver disease (NAFLD). This study indicated that PSPJ significantly reduced liver fat accumulation, the increase in blood lipids and ALT caused by HFD, indicating that PSPJ can prevent NAFLD. We demonstrated through cell experiments that PSPJ does not directly affect liver cells. The gut microbiota disorder and alterations in short-chain fatty acids (SCFAs) induced by the high-fat diet (HFD) were ameliorated by PSPJ, as evidenced by the analysis of 16S rRNA. In particular, supplementing PSPJ reduced the abundance of Turicibacter, Dubosiella, and Staphylococcus, and increased the abundance of Bacteroides, Blautia, and Lactobacillus. Untargeted metabolomic analysis shows that PSPJ improves liver metabolic disorders by regulating arachidonic acid metabolism, carbohydrate digestion and absorption, fatty acid biosynthesis, fatty acid metabolism and retinol metabolism. The findings of our investigation indicate that PSPJ has the potential to modulate liver metabolism through alterations in the composition of intestinal bacteria, hence preventing NAFLD.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease
    Mouzaki, Marialena
    Bandsma, Robert
    CURRENT DRUG TARGETS, 2015, 16 (12) : 1324 - 1331
  • [22] Gut microbiota and non-alcoholic fatty liver disease: new insights
    Aron-Wisnewsky, J.
    Gaborit, B.
    Dutour, A.
    Clement, K.
    CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) : 338 - 348
  • [23] Non-alcoholic fatty liver disease and the gut microbiota in adolescents: is there a relationship?
    El Amrousy, Doaa
    El Ashry, Heba
    Maher, Sara
    Elsayed, Yousef
    Hasan, Samir
    BMC PEDIATRICS, 2024, 24 (01)
  • [24] Polyphenols improve non-alcoholic fatty liver disease via gut microbiota: A comprehensive review
    Mohammadhasani, Kimia
    Fard, Mohammad Vahedi
    Shahri, Ali Mottaghi Moghaddam
    Khorasanchi, Zahra
    FOOD SCIENCE & NUTRITION, 2024, 12 (08): : 5341 - 5356
  • [25] Microbiota and non-alcoholic fatty liver disease
    Link, A.
    Thon, C.
    Sydor, S.
    Canbay, A.
    GASTROENTEROLOGE, 2019, 14 (03): : 179 - 184
  • [26] The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease
    Li, Zhonglin
    Yuan, Hang
    Chu, Huikuan
    Yang, Ling
    MICROORGANISMS, 2023, 11 (08)
  • [27] Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice
    Zhu, Lijun
    Xiao, Mingmei
    Luo, Jigang
    Li, Shijie
    Liu, Wenting
    Wu, Jinchuan
    Song, Zhuoyue
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 235
  • [28] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Ruiting Han
    Junli Ma
    Houkai Li
    Frontiers of Medicine, 2018, 12 : 645 - 657
  • [29] Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
    Doulberis, Michael
    Kotronis, Georgios
    Gialamprinou, Dimitra
    Kountouras, Jannis
    Katsinelos, Panagiotis
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 71 : 182 - 197
  • [30] New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer
    Ezzaidi, Niama
    Zhang, Xiang
    Coker, Olabisi Oluwabukola
    Yu, Jun
    CANCER LETTERS, 2019, 459 : 186 - 191